Naphthalimides and azonafides as promising anti-cancer agents

Current Medicinal Chemistry

Volumn 16, Issue 10, 2009, Pages 1192-1213

  Ingrassia, Laurent ^a   Lefranc, Florence ^b,c,d   Kiss, Robert ^b,d   Mijatovic, Tatjana ^a  

^a Unibioscreen SA   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c ERASME HOSPITAL   (Belgium)

^d FNRS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

6 ETHOXYAZONAFIDE; AMONAFIDE; AMP 53; ANTINEOPLASTIC AGENT; ARISTOLOCHIC ACID; AZAPHENANTHRENE DERIVATIVE; AZONAFIDE DERIVATIVE; BIBENOLINE; BISNAFIDE MESYLATE; CYCLOHEXIMIDE; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ELINAFIDE; ETHONAFIDE; ETOPOSIDE; GLUTARIMIDE; IMIDAZONAPHTHALIMIDE DERIVATIVE; IMIDE; LU 79553; MITONAFIDE; NAPHTHALIMIDE DERIVATIVE; NAPHTHALMUSTINE; PHENANTHRENE DERIVATIVE; PLATINUM COMPLEX; TETRAHYDROAZONAFIDE DERIVATIVE; THIAZONAPHTHALIMIDE DERIVATIVE; TILORONE; UNBS 5162; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA DERIVATIVE;

AMNESIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; CANCER CELL CULTURE; CANCER SURVIVAL; CARCINOMA; CLINICAL TRIAL; COLON CARCINOMA; COLORECTAL CANCER; CONTINUOUS INFUSION; CYTOTOXICITY; DISEASE MODEL; DRUG DESIGN; DRUG DNA BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; FATIGUE; HELA CELL; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; INFECTION; LEUKEMIA; LEUKOPENIA; LEWIS CARCINOMA; MALAISE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MUCOSA INFLAMMATION; MULTIDRUG RESISTANCE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROMUSCULAR DISEASE; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PROSTATE CANCER; PRURITUS; RECOMMENDED DRUG DOSE; REVIEW; RHABDOMYOSARCOMA; SARCOMA; SEPSIS; SOLID TUMOR; STOMATITIS; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG DESIGN; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; NAPHTHALIMIDES; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 65649135129     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709787846659     Document Type: Review

References (92)

1. Roldan, C. M.; Braña, M. F.; Berlanga, J. M. C. Butyramiden und verfahren zu dessen herstelling. Patent DE2318136, 1973.
2. Roldan, C. M.; Braña, M. F.; Berlanga, J. M. C. Naphthalimides substitutes. Patent FR2279396, 1976.
3. Braña, M. F.; Ramos, A. Naphthalimides as anticancer agents: synthesis and biological activity. Curr. Med. Chem. - Anti-Cancer Agents, 2001, 1, 237-255.
4. NCI database: http://dtp.nci.nih.gov/.
5. Zee-Cheng, R. K. Y.; Cheng, C. C. N-(Aminoalkyl)imide antineo-plastic agents. Synthesis and biological activity. J. Med. Chem., 1985, 28, 1216-1222.
6. Braña, M. F.; Castellano, J. M.; Morán, M.; Emling, F.; Kluge, M.; Schlick, E.; Klebe, G.; Walker, N. Synthesis, structure and antitumor activity of new benz[d,e]isoquinoline-1,3-diones. Arzneimittelforschung., 1995, 45, 1311-1318.
7. Braña, M. F.; Morán, M.; Pérez de Vega, M. J.; Pita-Romero, I.; Walker, N. Synthesis and cytostatic activity of enynes, enediynes and dienediynes linked to intercalators. Tetrahedron, 1995, 51, 9127-9138.
8. Braña, M. F.; Cacho, M.; García, M. A.; de Pascual-Teresa, B.; Ramos, A.; Domínguez, M. T.; Pozuelo, J. M.; Abradelo, C.; Rey-Stolle, M. F.; Yuste, M.; Bañez-Coronel, M.; Lacal, J. C. New analogues of amonafide and elinafide, containing aromatic heterocycles: synthesis, antitumor activity, molecular modeling, and DNA binding properties. J. Med. Chem., 2004, 47, 1391-1399.
9. Li, Z.; Yang, G.; Qian, X. Novel thiazonaphthalimides as efficient antitumor and DNA photocleaving agents: Effects of intercalation, side chains, and substituent groups. Bioorg. Med. Chem., 2005, 13, 4864-4870.
10. Li, F.; Cui, J.; Guo, L.; Qian, X.; Ren, W.; Wang, K.; Liu, F. Molecular design, chemical synthesis, and biological evaluation of '4-1' pentacyclic aryl/heteroaryl-imidazonaphthalimides. Bioorg. Med. Chem., 2007, 15, 5114-5121.
11. Xu, Y.; Qu, B.; Qian, X.; Li, Y. Five-member thio-heterocyclic fused naphthalimides with aminoalkyl side chains: Intercalation and photocleavage to DNA. Bioorg. Med. Chem. Lett., 2005, 15, 1139-1142.
12. Quian, X.; Li, Y.; Xu, Y.; Liu, Y.; Qu, B. Highly-efficient DNA photocleavers with long wavelength absorptions: Thio-heterocyclic fused naphthalimides containing aminoalkyl side chains. Bioorg. Med. Chem. Lett., 2004, 14, 2665-2668.
13. Yin, H.; Xu, Y.; Qian, X.; Li, Y.; Liu, J. Novel N-oxides of naphthalimides as prodrug leads against hypoxic solid tumor: Synthesis and biological evaluation. Bioorg. Med. Chem. Lett., 2007, 17, 2166-2170.
14. Pain, A.; Samanta, S.; Dutta, S.; Saxena, A. K.; Shanmugavel, M.; Kampasi, H.; Qazi, G. N.; Sanyal. U. Evaluation of naphthalmustine, a nitrogen mustard derivative of naphthalimide as a rationally-designed anticancer agent. J. Exp. Clin. Cancer Res., 2003, 22, 411-418.
15. Van Quaquebeke, E.; Mahieu, T.; Dumont, P.; Dewelle, J.; Ribaucour, F.; Simon, G.; Sauvage, S.; Gaussin, J.F.; Tuti, J.; El Yazidi, M.; Van Vynckt, F.; Mijatovic, T.; Lefranc, F.; Darro, F.; Kiss, R. 2,2,2-Trichloro-N-({2-[2-(dimethylamino)ethyl]-1,3-dioxo-2,3-dihydro-1H- benzo[de]isoquinolin- 5-yl}carbamoyl)acetamide (UN BS3157), a novel nonhematotoxic naphthalimide derivative with potent antitumor activity. J. Med. Chem., 2007, 50, 4122-4134.
16. Van Quaquebeke, E.; Simon, G.; Van Den Hove, L.; Kiss, R.; Darro, F. Naphthalimide derivatives for the treatment of cancer. Patent EP1593672, 2005.
17. Mijatovic, T.; Mahieu, T.; Bruyère, C.; De Nève, N.; Dewelle, J.; Simon, G.; Dehoux, M. J. M.; Van der Aar, E.; Haibe-Kains, B.; Bontempi, G.; Decaestecker, C.; Van Quaquebeke, E.; Darro, F.; Kiss, R. UNBS5162, a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers. Neoplasia, 2008, 10, 573-586.
18. Van Quaquebeke, E.; Simon, G.; El Yazidi, M.; Van den Hove, L.; Darro, F.; Kiss, R. 5-urea substituted naphthalimide derivatives, methods of production and pharmaceutical compositions for treating cancer. Patent WO2007128538, 2007.
19. Norton, J. T.; Witschi, M. A.; Luong, L.; Kawamura, A.; Ghosh, S.; Stack, M. S.; Sim, E.; Avram, M. J.; Apella, D. H.; Huang, S. Synthesis and anticancer activities of 6-amino amonafide derivatives. Anti-cancer Drugs, 2008, 19, 23-36.
20. Bayer, A.G. Basically substituted bis-naphthalimides and their production. Patent GB1069337, 1967.
21. Arnold, F. E.; Hedberg, F. L. Ethynyl-substituted bis-naphthalimides. Patent US4151358, 1979.
22. Braña, M. F.; Castellano, J. M.; Keilhauer, G.; Schlick, E. Bis-naphthalimides, their preparation and use. Patent EP0281902, 1988.
23. Braña, M. F.; Castellano, J. M.; Morán, M.; Pérez de Vega, M. J.; Romerdahl, C. R.; Qian, X.-D.; Bousquet, P. F.; Emling, F.; Schlick, E.; Keilhauer, G. Bis-naphthalimides: A new class of antitumor agents. Anti-Cancer Drug Des., 1993, 8, 257-268.
24. Braña, M. F.; Castellano, J. M.; Morán, M.; Pérez de Vega, M. J.; Perron, D.; Conlon, D.; Bousquet, P. F.; Romerdahl, C. A.; Robinson, S. P. Bis-naphthalimides 3: Synthesis and antitumor activity of N,N'-bis[2-(1,8-naphthalimido)-ethyl] alkanediamines. Anti-Cancer Drug Des., 1996, 11, 297-309.
25. Bousquet, P. F.; Braña, M. F.; Conlon, D.; Fitzgerald, K. M.; Perron, D.; Cocchiaro, C.; Miller, R.; Morán, M.; George, J.; Qian, X. D.; Keilhauer, G.; Romerdahl, C. A. Preclinical evaluation of LU 79553: A novel bis-naphthalimide with potent antitumor activity. Cancer Res., 1995, 55, 1176-1180.
26. Pérez, J. M.; López-Solera, I.; Montero, E. I.; Braña, M. F.; Alonso, C.; Robinson, S. P.; Navarro-Ranninger, C. Combined effect of platination and intercalation upon DNA binding of novel cytotoxic Pt-bis(naphthalimide) complexes. J. Med. Chem., 1999, 42, 5482-5486.
27. Patten, A. D.; Sun, J.-H, Ardecky, R. J. Bis-naphthalimides as anticancer agents. Patent US5086059, 1992.
28. Braña, M. F.; Castellano, J. M.; Morán, M.; Perez de Vega, M. J.; Qian, X. D.; Romerdahl, C. A.; Keilhauer, G. Bis-naphthalimides. 2. Synthesis and biological activity of 5,6-acenaphthalimidoalkyl-1,8-naphthalimidoalkyl amines. Eur. J. Med. Chem., 1995, 30, 235-239.
29. Braña, M. F.; Cacho, M.; Ramos, A.; Domínguez, M. T.; Pozuelo, J. M.; Abradelo, C.; Rey-Stolle, M. F.; Yuste, M.; Carrasco, C.; Bailly, C. Synthesis, biological evaluation and DNA binding properties of novel mono and bisnaphthalimides. Org. Biomol. Chem., 2003, 1, 648-654.
30. Braña, M. F.; Cacho, M.; García, M. A.; de Pascual-Teresa, B.; Ramos, A.; Domínguez, M. T.; Pozuelo, J. M.; Abradelo, C.; Rey-Stolle, M. F.; Yuste, M.; Báñez-Coronel, M.; Lacal, J. C. New analogues of amonafide and elinafide, containing aromatic heterocycles: Synthesis, antitumor activity, molecular modeling, and DNA binding properties. J. Med. Chem., 2004, 47, 1391-1399.
31. Sun, J.-H (The DuPont Merck Pharm. Co) Bis-naphthalimides containing amino-acid derived linkers as anticancer agents. Patents EP506008, EP 577753, JP 94506229, US5206249, WO9217453, 1992.
32. Casey; Robinson, P.; Robinson, K. A.; Castañoner, J. Bisnafide mesylate: Antineoplastic. Drugs Future, 1996, 21, 239-244.
33. Sami, S. M.; Dorr, R. T.; Remers, W. A. 2-substituted 1,2-dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. A new class of antitumor agent. J. Med. Chem., 1993, 36, 765-770.
34. Sami, S. M.; Dorr, R. T.; Solyom, A. M.; Alberts, D. S.; Remers, W. A. Amino-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz [de,h]isoquinoline-1, 3-diones. Synthesis, antitumor activity, and quantitative structure - activity relationship. J. Med. Chem., 1995, 38, 983-993.
35. Sami, S. M.; Dorr, R. T.; Solyom A. M.; Alberts, D. S.; Iyengar B. S.; Remers, W. A. 6- and 7-substituted 2-[2'-(dimethylamino) ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: Synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships. J. Med. Chem., 1996, 39, 1609-1618.
36. Sami, S. M.; Dorr, R. T.; Alberts, D. S.; Solyom A. M.; Remers, W. A. 2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h] isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships. J. Med. Chem., 1996, 39, 4978-4987.
37. Sami, S. M.; Dorr, R. T.; Alberts, D. S.; Solyom A. M.; Remers, W. A. Analogues of amonafide and azonafide with novel ring systems. J. Med. Chem., 2000, 43, 3067-3073.
38. Braña, M. F.; Castellano, J. M.; Perron, D.; Moran, M.; Perez de Vega, M.; Romerdahl, C. A.; Qian, X.-D.; Bousquet, P. F.; Emling, F.; Schlick, E.; Keilhauer, G. Bis-naphthalimides: A new class of antitumor agents. Anti-Cancer Drug Des., 1993, 8, 257-268.
39. Braña, M. F.; Castellano, J. M.; Perron, D.; Maher, C.; Conlon, D.; Bousquet, P. F.; George, J.; Qian, X.-D.; Robinson, S. P. Chromophore-modified bis-naphthialimides: Synthesis and antitumor activity of bis-dibenz[de,h]isoquinoline-1,3-diones. J. Med. Chem., 1997, 40, 449-454.
40. Chau, M.; Christensen, J. L.; Ajami, A. M; Capizzi, R. L. Amonafide, a topoisomerase II inhibitor, is unaffected by P-glycoprotein-mediated efflux. Leuk. Res., 2008, 32, 465-473.
41. Zhu, H.; Huang, M.; Yang, F.; Chen, Y.; Miao, Z. H.; Qian, X. H.; Xu, Y. F.; Qin, Y. X.; Luo, H. B.; Shen, X.; Geng, M. Y.; Cai, Y. J.; Ding, J. R16; a novel amonafide analogue; induces apoptosis and G2-M arrest via poisoning topoisomerase II. Mol. Cancer. Ther., 2007, 6, 484-495.
42. Houghton, P. J.; Cheshire, P. J.; Hallman, J. C. 3rd; Gross, J. L.; McRipley, R. J.; Sun J. H.; Behrens, C. H.; Dexter, D. L.; Houghton, J. A. Evaluation of a novel bis-naphthalimide anticancer agent; DMP 840; against human xenografts derived from adult; juvenile; and pediatric cancers. Cancer Chemother. Pharmacol., 1994, 33, 265-272.
43. Dorr, R. T.; Liddil, J. D.; Sami, S. M.; Remers, W.; Hersh, E. M.; Alberts, D. S. Preclinical antitumor activity of the azonafide series of anthracene-based DNA intercalators. Anticancer Drugs, 2001, 12, 213-220.
44. Alami, N.; Paterson, J.; Belanger, S.; Juste, S.; Grieshaber, C. K.; Leyland-Jones, B. Comparative analysis of xanafide cytotoxicity in breast cancer cell lines. Br. J. Cancer, 2007, 97, 58-64.
45. Pourpak, A.; Landowski, T. H.; Dorr, R. T. Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells. J. Pharmacol. Exp. Ther., 2007, 321, 1109-1117.
46. McRipley, R. J.; Burns-Horwitz, P. E.; Czerniak, P. M.; Diamond, R. J.; Diamond, M. A.; Miller, J. L.; Page, R. J.; Dexter, D. L.; Chen, S. F.; Sun,J. H.; Behrens, C. H.; Seitz, S. P.; Gross, J. L. Efficacy of DMP 840: A novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity. Cancer Res., 1994, 54, 159-164.
47. Czerniak, P.; McRipley, R.; Behrens, C. H.; et al. Magnitude and duration of anti-tumor response caused by DMP 840, a novel bis-naphthalimide anti-tumor agent, against human solid tumor xenografts in vivo. Proc. Amer. Assoc. Cancer Res., 1993, 34, Abstract 2289.
48. Houghton, P. J.; Cheshire, P. J; Hallman, J.; Sun, J.-H.; Behrens, C. H.; McRipley, R. J.; Gross, J. L. Evaluation of DMP 840, a novel antitumor agent in xenografts derived from adult and childhood malignancies. Proc. Amer. Assoc. Cancer Res., 1993, 34, 2293. (Abstract).
49. LoRusso, P.; Demchik, L.; Dan, M.; Polin, L.; Gross, J. L.; Corbett, T. H. Comparative efficacy of DMP 840 against mouse and human solid tumor models. Invest. New Drugs, 1995, 13, 195-203.
50. Arthaud, L.E; Springer, J. K. Preclinical toxicity of the anticancer agent DMP 840 in mice, rats and dog. Proc. Amer. Assoc. Cancer Res., 1993, 34, Abstract 2290.
51. Chen, A. Y.; Liu, L.F. DNA topoisomerases: Essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol., 1994, 34, 191-218.
52. Wang, J. C. Cellular roles of DNA topoisomerases: A molecular perspective. Nat. Rev. Mol. Cell Biol., 2002, 3, 430-440.
53. Liu, L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem., 1989, 58, 351-375.
54. Andoh, T.; Ishida, R. Catalytic inhibitors of DNA topoisomerase II. Biochim. Biophys. Acta, 1998, 1400, 155-171.
55. Hsiang, Y. H.; Jiang, J. B.; Liu, L. F. Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs. Mol. Pharmacol., 1989, 36, 371-376.
56. Bear, S.; Remers, W. A. Computer simulation of the binding of amonafide and azonafide to DNA. J. Comput. Aided Mol. Des., 1996, 10, 165-175.
57. Wang, H.; Mao, Y.; Zhou, N.; Hu, T.; Hsieh, T. S; Liu, L. F. Atp-bound topoisomerase II as a target for antitumor drugs. J. Biol. Chem., 2001, 276, 15990-15995.
58. Mayr, C. A.; Sami, S. A.; Dorr, R. T. In vitro cytotoxicity and DNA damage production in Chinese hamster ovary cells and topoisomerase II inhibition by 2-[2-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones with substitutions at the 6-and 7- positions (azonafides). Anti-Cancer Drugs, 1997, 8, 245-256.
59. Nitiss, J. L.; Zhou, J.; Rose, A.; Hsiung, Y.; Gale, K. C.; Osheroff, N. The bis(naphthalimide) DMP-840 causes cytotoxicity by its action against eukaryotic topoisomerase II. Biochemistry, 1998, 37, 3078-3085.
60. Gallego, J.; Reid, B. R. Solution structure and dynamics of a complex between DNA and the antitumor bisnaphthalimide LU-79553: Intercalated ring flipping on the millisecond time scale. Biochemistry, 1999, 38, 15104-15115.
61. Bailly, C.; Braña, M.; Waring, M. J. Sequence-selective intercalation of antitumour bis-naphthalimides into DNA. Evidence for an approach via the major groove. Eur. J. Biochem., 1996, 240, 195-208.
62. Flores, L. V.; Staples, A. M.; Mackay, H.; Howard, C. M.; Uthe, P. B.; Sexton, J. S. 3rd; Buchmueller, K. L.; Wilson, W. D.; O'Hare, C.; Kluza, J.; Hochhauser, D.; Hartley, J. A.; Lee, M. Synthesis and evaluation of an intercalator-polyamide hairpin designed to target the inverted CCAAT box 2 in the topoisomerase II alpha promoter. Chembiochem., 2006, 7, 1722-1729.
63. Braña, M.F.; Castellano, J.M.; Roldán, C.M.; Santos, A.; Vázquez, D.; Jiménez, A. Synthesis and mode(s) of action of a new series of imide derivatives of 3-nitro-1,8 naphthalic acid. Cancer Chemother. Pharmacol., 1980, 4, 61-66.
64. Bailly, C.; Carrasco, C.; Joubert, A.; Bal, C.; Wattez, N.; Hildebrand, M. P.; Lansiaux, A.; Colson, P.; Houssier, C.; Cacho, M.; Ramos, A; Braña, M. F. Chromophore-modified bisnaphthalimides: DNA recognition, topoisomerase inhibition, and cytotoxic properties of two mono- and bisfuronaphthalimides. Biochemistry, 2003, 42, 4136-4150.
65. Chen, S. F.; Behrens, D. L; Behrens, C. H.; Czerniak, P.M.; Dexter, D. L.; Dusak, B. L.; Fredericks, J. R.; Gale, K. C.; Gross, J. L.; Jiang, J. B.; Kirshenbaum, M. R.; McRipley, R., J.; Papp, L. M.; Patten, A. D.; Perrella, F. W.; Seitz, S. P.; Stafford, M. P.; Sun, J. H.; Sun, T.; Wuonola, M. A.; Von Hoff, D. D. XB596, a promising bis-naphthalimide anti-cancer agent. Anticancer Drugs, 1993, 4, 447-457.
66. Pervaiz, S. Reactive oxygen-dependent production of novel photo-chemotherapeutic agents. FASEB J., 2001, 15, 612-617.
67. Suzuki, K.; Nagasawa, H.; Uto, Y.; Sugimoto, Y.; Noguchi, K.; Wakida, M; Wierzba, K.; Terada, T.; Asao, T.; Yamada, Y.; Kitazato, K.; Hori, H. Naphthalimidobenzamide DB-51630: A novel DNA binding agent inducing p300 gene expression and exerting a potent anti-cancer activity. Bioorg, Med. Chem., 2005, 13, 4014-4021
68. Schlicker, A.; Peschke, P.; Bürkle, A.; Hahn, E. W.; Kim, J. H. 4-Amino-1,8-naphthalimide: A novel inhibitor of poly(ADP-ribose) polymerase and radiation sensitizer. Int. J. Radiat. Biol., 1999, 75, 91-100.
69. Noël, G.; Godon, C.; Fernet, M.; Giocanti, N.; Mégnin-Chanet, F.; Favaudon, V. Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis. Mol. Cancer Ther., 2006, 5, 564-574.
70. Huang, S.; Deerinck, T. J.; Ellisman, M. H.; Spector, D. L. The perinucleolar compartment and transcription. J. Cell. Biol., 1998, 143, 35-47.
71. Kopp, K.; Huang, S. Perinucleolar compartment and transformation. J. Cell Biochem., 2005, 95, 217-225.
72. Kamath, R.V.; Thor, A. D.; Wang, C.; Edgerton, S. M.; Slusarczyk, A.; Leary, D. J.; Wang, J.; Wiley, E. L.; Jovanovic, B.; Wu, Q.; Nayar, R.; Kovarik, P.; Shi, F.; Huang, S. Perinucleolar compartment prevalence has an independent prognostic value for breast cancer. Cancer Res., 2005, 65, 246-253.
73. Norton, J.T.; Pollock, C. B.; Wang, C.; Schink, J. C.; Kim, J. J.; Huang, S. Perinucleolar compartment prevalence is a phenotypic pancancer marker of malignancy. Cancer, 2008, 113, 861-869.
74. Saez, R.; Craig, J. B.; Kuhn, J.G.; Weiss, G. R.; Koeller, J.; Phillips, J.; Havlin, K.; Harman, G.; Hardy, J.; Melink, T. J. Phase I clinical investigation of amonafide. J. Clin. Oncol., 1989, 7, 1351-1358.
75. Ratain, M. J.; Mick, R.; Berezin, F.; Janish, L.; Schilsky, R. L.; Williams, S. F.; Smiddy, J. Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin. Pharmacol. Ther., 1991, 50, 573-579.
76. Felder, T. B.; McLean, M. A.; Vestal, M. L.; Lu, K.; Farquhar, D.; Legha, S. S.; Shah, R.; Newman, R. A. Pharmacokinetics and metabolism of the antitumor drug amonafide (NSC-308847) in humans. Drug Metab. Dispos., 1987, 15, 773-778.
77. Ratain, M. J.; Mick, R.; Berezin, F.; Janish, L.; Schilsky, R. L.; Vogelzang, N. J.; Lane, L. B. Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res., 1993, 53, 2304-2308.
78. Ratain, M. J.; Mick, R.; Janish, L.; Berezin, F.; Schilsky, R. L.; Vogelzang, N. J.; Kut, M. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender. Pharmacogenetics, 1996, 6, 93-101.
79. Díaz-Rubio, E.; Martín, M.; López-Vega, J. M.; Casado, A.; Benavides, A. Phase I study of mitonafide with a 3-day administration schedule: Early interruption due to severe central nervous system toxicity. Invest. New Drugs, 1994, 12, 277-281.
80. Llombart, M.; Poveda, A.; Forner, E.; Fernández-Martos, C.; Gaspar, C.; Muñoz, M.; Olmos, T.; Ruiz, A.; Soriano, V.; Benavides, A.; Martin, M.; Schlick, E.; Guillem, V. Phase I study of mitonafide in solid tumors. Invest. New Drugs, 1992, 10,
81. Rosell, R.; Carles, J.; Abad, A.; Ribelles, N.; Barnadas, A.; Benavides, A.; Martin, M. Phase I study of mitonafide in 120 hour continuous infusion in non-small cell lung cancer. Invest. New Drugs, 1992, 10, 171-175.
82. Villalona-Calero, M. A.; Eder, J. P.; Toppmeyer, D. L.; Allen, L. F.; Fram, R.; Velagapudi, R.; Myers, M.; Amato, A.; Kagen-Hallet, K.; Razvillas, B.; Kufe, D. W.; Von Hoff, D. D.; Rowinsky, E. K. Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies. J. Clin. Oncol., 2001, 19, 857-869.
83. Awada, A.; Thödtmann, R.; Piccart, M. J.; Wanders, J.; Schrijvers, A. H.; Von Broen, I. M.; Hanauske, A. R. EORTC-ECSG phase I study. An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours. Eur. J. Cancer, 2003, 39, 742-747.
84. O'Reilly, S.; Rowinsky, E. K.; Grochow, L.; Adjei, A.; Bowling, K.; Slichenmyer, W.; Sartorius, S.; Finizio, M.; Gray, J. E.; Pieniaszek, H. J.; Peterman, V. C.; Mabring, D.; Donehower, R. C. Phase I and pharmacologic study of DMP 840 as a 24 hour infusion in patients with solid tumors. ASCO Annual Meeting, 1995.
85. Cobb, P.; Burris, H.; Drengler, R.; Fields, S.; Smith, L.; White, L.; Pieniaszek, H.; Gray, J.; Peterman, V.; Finizio, M.; Von Hoff; D. Phase I trial of DMP 840 given as a 120-hr continuous infusion every 28 days. ASCO Annual Meeting, 1995.
86. Abad, A.; Grávalos, C.; Font, A.; Molina, F.; Díaz-Puente, M. T.; Fabregat, X.; Benavides, A.; Martín, M. Phase II study of Mitonafide in advanced and relapsed colorectal cancer. Invest. New Drugs, 1996, 14, 223-225.
87. Casado, A.; Rosell, R.; García-Gómez, R.; Díaz-Rubio, E.; Pérez-Manga, G.; Font, A.; Benavides, A.; Martín, M. Phase II study of mitonafide in non-small cell lung cancer (NSCLC). Invest. New Drugs, 1996, 14, 415-417.
88. Mitchell, R.B.; Goss, G.; Guarino, M.; Keaton, M.; Hammond, N.; Finizio, M.; Gray, J. Phase II trial of bisnafide in advanced nonsmall cell lung cancer (NSCLC). ASCO Annual Meeting 1996.
89. Kline, R. C.; Melnychuk, D.; Schiano, M.; Reynolds, K.; Fung Kee Fung, M.; Finan, M. A.; Finizio, M.; Gray, J. A phase II multicenter clinical trial of bisnafide in women with advanced refractory ovarian carcinoma. ASCO Annual Meeting 1996.
90. Samanta, S.; Pain, A.; Dutta, S.; Saxena, A. K.; Shanmugavel, M.; Pandita, R. M.; Qazi, G. N.; Sanyal, U. Antitumor activity of Nitronaphthal-NU, a novel mixed-function agent. J. Exp. Ther. Oncol., 2005, 5, 15-22.
91. Samanta, S.; Pain, A.; Dutta, S.; Sanyal, U. Evaluation of naphthal-NU, a 2-chloroethylnitrosourea derivative of naphthalimide, as a mixed-function anticancer agent. J. Exp. Clin. Cancer Res., 2002, 21, 87-93.
92. Von Hoff, D. D. There are no bad anticancer agents, only bad clinical trial designs - Twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin. Cancer Res., 1998, 4, 1079-1086.